Evidence map›Paper›PMID 31623187›Full record

ReviewMicroorganisms2019

Pathogenetic Impact of Bacterial-Fungal Interactions.

Filomena Nogueira, Shirin Sharghi, Karl Kuchler, Thomas Lion

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Microorganisms, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04554693 (The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery), which is not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04554693 phase4terminatednot on this mapstarted 2020, after this paper: background citation

The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery: A Prospective, Randomized, Placebo-Controlled Trial

TypeinterventionalSponsorUniversity of LouisvilleRan2020 to 2023Enrolled78ConditionsEndometriosis, Endometriosis-related PainArmsMetronidazole Oral, Placebo
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Review
  3. InvestigatingIJID regions · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Mechanism ofApplied and environmental microbiology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Fungi in cancer.Nature reviews. Cancer · 2024
    Article
  17. EFFECT OFAfrican journal of infectious diseases · 2024
    Article
  18. Review
  19. Review
  20. Top five unanswered questions in fungal cell surface research.Cell surface (Amsterdam, Netherlands) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Filomena NogueiraCCRI-St. Anna Children's Cancer Research Institute, Vienna 1090, Austria. filomena.nogueira@ccri.at.
Shirin SharghiCCRI-St. Anna Children's Cancer Research Institute, Vienna 1090, Austria. shirin.sharghi@ccri.at.
Karl KuchlerCenter of Medical Biochemistry, Max Perutz Labs, Campus Vienna Biocenter, Medical University of Vienna, Vienna 1030, Austria. karl.kuchler@meduniwien.ac.at.ORCID 0000-0003-2719-5955
Thomas LionCCRI-St. Anna Children's Cancer Research Institute, Vienna 1090, Austria. thomas.lion@ccri.at.
Max Perutz Labs · ATSt Anna Children's Hospital · AT

Funding

FP7 Framework Programme 602125
6 · The paper itself

Abstract

Polymicrobial infections are of paramount importance because of the potential severity of clinical manifestations, often associated with increased resistance to antimicrobial treatment. The intricate interplay with the host and the immune system, and the impact on microbiome imbalance, are of importance in this context. The equilibrium of microbiota in the human host is critical for preventing potential dysbiosis and the ensuing development of disease. Bacteria and fungi can communicate via signaling molecules, and produce metabolites and toxins capable of modulating the immune response or altering the efficacy of treatment. Most of the bacterial-fungal interactions described to date focus on the human fungal pathogen

Indexed as

bacterial–fungal interactionsimmune responsein vivo modelsmicrobiomemolecules

Identifiers

PMID31623187
PMCPMC6843596
OpenAlexW2980464791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.